This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels | MicrobiomeTrials
← Back to trials NCT07538518
PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels Recruiting OBSERVATIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-10-01Est. Completion: 2028-03-15
Enrollment target: 25 participantsLocations One Boston Medical Center Place, Boston, Massachusetts, United States Columbia University Irving Medical Center, New York, New York, United States Bill and Rita Clements Advanced Medical Imaging Center, Dallas, Texas, United States Other microbiome trials you might be interested in Amyloidosis in Transthyretin (TTR) Amyloidosis, Familial Amyloid Cardiomyopathy Amyloid Cardiomyopathy, Transthyretin-Related Amyloidogenic Transthyretin (ATTR) Amyloidosis Heart Disease Cardiomyopathies Amyloidosis, Hereditary, Transthyretin-Related Polyneuropathies Amyloidosis
The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amy…
Multiple Locations Est. completion Nov 2037
TERMINATED
Hereditary (familial) amyloidosis arising from the misfolding of a mutated or variant transthyretin, is the most frequen…
Fort-de-France, Martinique Completed Sep 30, 2019